OHR Pharmaceutical Inc. (OHRP) and Avid Bioservices Inc. (NASDAQ:CDMO) Comparing side by side

We will be contrasting the differences between OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Avid Bioservices Inc. (NASDAQ:CDMO) as far as profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OHR Pharmaceutical Inc. N/A 0.00 9.98M -3.54 0.00
Avid Bioservices Inc. 36.53M 6.37 23.90M -0.48 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us OHR Pharmaceutical Inc. and Avid Bioservices Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
OHR Pharmaceutical Inc. 0.00% -71.5% -66.8%
Avid Bioservices Inc. -65.43% -33.1% -19.9%

Volatility & Risk

OHR Pharmaceutical Inc. has a 1.17 beta, while its volatility is 17.00%, thus making it more volatile than S&P 500. Avid Bioservices Inc. has a 2.63 beta and it is 163.00% more volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of OHR Pharmaceutical Inc. are 5.4 and 5.4 respectively. Its competitor Avid Bioservices Inc.’s Current Ratio is 2.3 and its Quick Ratio is 1.8. OHR Pharmaceutical Inc. can pay off short and long-term obligations better than Avid Bioservices Inc.

Insider & Institutional Ownership

Roughly 12.7% of OHR Pharmaceutical Inc. shares are held by institutional investors while 49.3% of Avid Bioservices Inc. are owned by institutional investors. OHR Pharmaceutical Inc.’s share held by insiders are 8.89%. Insiders Competitively, held 11.62% of Avid Bioservices Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OHR Pharmaceutical Inc. 3.29% -17.91% -31.21% -43.18% -50.81% 27.91%
Avid Bioservices Inc. -1.48% 3.9% -23.08% -37.79% 60.64% -2.44%

For the past year OHR Pharmaceutical Inc. had bullish trend while Avid Bioservices Inc. had bearish trend.

Summary

Avid Bioservices Inc. beats OHR Pharmaceutical Inc. on 5 of the 9 factors.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.